➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Harvard Business School
Moodys
McKesson
Colorcon

Last Updated: September 28, 2021

DrugPatentWatch Database Preview

Deferiprone - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

What are the generic drug sources for deferiprone and what is the scope of patent protection?

Deferiprone is the generic ingredient in two branded drugs marketed by Chiesi, Hikma, and Taro Pharm Inds Ltd, and is included in five NDAs. There are five patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Deferiprone has fifty-four patent family members in twenty-seven countries.

There are four drug master file entries for deferiprone. Four suppliers are listed for this compound.

Recent Clinical Trials for deferiprone

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
First Affiliated Hospital of Fujian Medical UniversityEarly Phase 1
David HasanPhase 2
Ministry of Health, FrancePhase 2/Phase 3

See all deferiprone clinical trials

Pharmacology for deferiprone
Drug ClassIron Chelator
Mechanism of ActionIron Chelating Activity
Anatomical Therapeutic Chemical (ATC) Classes for deferiprone
Paragraph IV (Patent) Challenges for DEFERIPRONE
Tradename Dosage Ingredient NDA Submissiondate
FERRIPROX TABLET;ORAL deferiprone 021825 2016-01-29

US Patents and Regulatory Information for deferiprone

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chiesi FERRIPROX deferiprone TABLET;ORAL 212269-001 May 19, 2020 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Hikma DEFERIPRONE deferiprone TABLET;ORAL 213239-001 Mar 29, 2021 AB RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Chiesi FERRIPROX deferiprone TABLET;ORAL 021825-002 Jul 25, 2019 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-002 Apr 20, 2018 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Chiesi FERRIPROX deferiprone TABLET;ORAL 021825-001 Oct 14, 2011 AB RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Chiesi FERRIPROX deferiprone TABLET;ORAL 212269-001 May 19, 2020 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for deferiprone

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Chiesi FERRIPROX deferiprone TABLET;ORAL 021825-001 Oct 14, 2011 ⤷  Free Forever Trial ⤷  Free Forever Trial
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-002 Apr 20, 2018 ⤷  Free Forever Trial ⤷  Free Forever Trial
Chiesi FERRIPROX deferiprone TABLET;ORAL 212269-001 May 19, 2020 ⤷  Free Forever Trial ⤷  Free Forever Trial
Chiesi FERRIPROX deferiprone TABLET;ORAL 021825-002 Jul 25, 2019 ⤷  Free Forever Trial ⤷  Free Forever Trial
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-001 Sep 9, 2015 ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for deferiprone

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2009129592 ⤷  Free Forever Trial
Eurasian Patent Organization 022751 ⤷  Free Forever Trial
Germany 60138189 ⤷  Free Forever Trial
Ukraine 102254 ⤷  Free Forever Trial
Cyprus 1116146 ⤷  Free Forever Trial
South Africa 200109322 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Harvard Business School
Moodys
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.